CIITA Antibody (7-1H): sc-13556

CIITA Antibody (7-1H) is a mouse monoclonal IgG1 kappa light chain antibody that detects CIITA protein of mouse, rat, and human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and immunohistochemistry (IHC). CIITA (7-1H) antibody is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase, phycoerythrin, fluorescein isothiocyanate, and multiple Alexa Fluor® conjugates. CIITA protein plays a crucial role in the immune response by acting as a master regulator of major histocompatibility complex (MHC) class II gene expression, which is essential for the presentation of antigens to CD4+ T cells. This process is vital for the activation of adaptive immunity, as CD4+ T cells recognize and respond to pathogens. CIITA′s function is particularly important in immune system development, as defects in CIITA can lead to severe immunodeficiencies, such as Bare Lymphocyte Syndrome, characterized by the absence of MHC class II molecules on the cell surface. Expression of CIITA is induced by interferon-gamma through JAK1 and Stat1 signaling pathways, highlighting a role in immune responses to infections. CIITA interacts with various proteins, including RFX-B, which is part of the RFX complex necessary for MHC class II transcription, further emphasizing intricate regulatory mechanisms governing immune responses.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

CIITA Antibody (7-1H) References:

1. Analysis of the defect in IFN-gamma induction of MHC class II genes in G1B cells: identification of a novel and functionally critical leucine-rich motif (62-LYLYLQL-68) in the regulatory factor X 5 transcription factor.  |  Brickey, WJ., et al. 1999. J Immunol. 163: 6622-30. PMID: 10586057
2. Genome-wide CIITA-binding profile identifies sequence preferences that dictate function versus recruitment.  |  Scharer, CD., et al. 2015. Nucleic Acids Res. 43: 3128-42. PMID: 25753668
3. FBXO11 constitutes a major negative regulator of MHC class II through ubiquitin-dependent proteasomal degradation of CIITA.  |  Kasuga, Y., et al. 2023. Proc Natl Acad Sci U S A. 120: e2218955120. PMID: 37279268
4. The NLR member CIITA: Master controller of adaptive and intrinsic immunity and unexpected tool in cancer immunotherapy.  |  Forlani, G., et al. 2023. Biomed J. 46: 100631. PMID: 37467968
5. LncRNA-HOXC-AS2 regulates tumor-associated macrophage polarization through the STAT1/SOCS1 and STAT1/CIITA pathways to promote the progression of non-small cell lung cancer.  |  Yin, C., et al. 2024. Cell Signal. 115: 111031. PMID: 38168631
6. Molecular analysis of G1B and G3A IFN gamma mutants reveals that defects in CIITA or RFX result in defective class II MHC and Ii gene induction.  |  Chin, KC., et al. 1994. Immunity. 1: 687-97. PMID: 7600294
7. Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (or bare lymphocyte syndrome).  |  Steimle, V., et al. 1993. Cell. 75: 135-46. PMID: 8402893
8. Regulation of transcription of MHC class II genes.  |  Boss, JM. 1997. Curr Opin Immunol. 9: 107-13. PMID: 9039770
9. Specific complex formation between the type II bare lymphocyte syndrome-associated transactivators CIITA and RFX5.  |  Scholl, T., et al. 1997. Proc Natl Acad Sci U S A. 94: 6330-4. PMID: 9177217
10. Regulatory factor X, a bare lymphocyte syndrome transcription factor, is a multimeric phosphoprotein complex.  |  Moreno, CS., et al. 1997. J Immunol. 158: 5841-8. PMID: 9190936
11. A gene encoding a novel RFX-associated transactivator is mutated in the majority of MHC class II deficiency patients.  |  Masternak, K., et al. 1998. Nat Genet. 20: 273-7. PMID: 9806546
12. MHC class II gene silencing in trophoblast cells is caused by inhibition of CIITA expression.  |  Morris, AC., et al. 1998. Am J Reprod Immunol. 40: 385-94. PMID: 9894561

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-CIITA Antibody (7-1H) has 42 citations in a variety of scientific publications.

Primary antibodies like Anti-CIITA Antibody (7-1H) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

CIITA Antibody (7-1H) Specifications

Alternate Product Name: C2TA

Product Clone Name: 7-1H

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁ kappa light chain

Amino Acids: 1-350

Epitope Target: CIITA

Epitope Species: human

Product Reactivity/Detection: CIITA

Species Reactivity/Detection: mouse, rat, human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, IHC(P)

Vialing Information: Each vial contains 200 µg IgG₁ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 42 citations in various scientific publications

Available Conjugates/Forms for CIITA Antibody (7-1H): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, PE: Phycoerythrin, X: TransCruz Reagent